Is Contineum Therapeutics, Stock a Good Investment?
Contineum Therapeutics, Investment Advice | CTNM |
- Examine Contineum Therapeutics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Contineum Therapeutics,'s leadership team and their track record. Good management can help Contineum Therapeutics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Contineum Therapeutics,'s business and its evolving consumer preferences.
- Compare Contineum Therapeutics,'s performance and market position to its competitors. Analyze how Contineum Therapeutics, is positioned in terms of product offerings, innovation, and market share.
- Check if Contineum Therapeutics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Contineum Therapeutics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Contineum Therapeutics, Class stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Contineum Therapeutics, Class is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Contineum Therapeutics, Stock
Researching Contineum Therapeutics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 83.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Contineum Therapeutics, recorded a loss per share of 2.18. The entity had not issued any dividends in recent years.
To determine if Contineum Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Contineum Therapeutics,'s research are outlined below:
| Contineum Therapeutics, generated a negative expected return over the last 90 days | |
| Contineum Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (42.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Contineum Therapeutics, generates negative cash flow from operations | |
| Contineum Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Quantisnow |
Earnings surprises can significantly impact Contineum Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Contineum Therapeutics,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.3467 | -0.39 | -0.0433 | 12 | ||
2025-03-07 | 2024-12-31 | -0.435 | -0.56 | -0.125 | 28 | ||
2024-05-16 | 2024-03-31 | -0.46 | -3.55 | -3.09 | 671 |
Contineum Therapeutics, Target Price Consensus
Contineum target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Contineum Therapeutics,'s target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Contineum analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Contineum stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Contineum Therapeutics,, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationContineum Therapeutics, Target Price Projection
Contineum Therapeutics,'s current and average target prices are 7.07 and 28.67, respectively. The current price of Contineum Therapeutics, is the price at which Contineum Therapeutics, Class is currently trading. On the other hand, Contineum Therapeutics,'s target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Contineum Therapeutics, Market Quote on 28th of March 2025
Target Price
Analyst Consensus On Contineum Therapeutics, Target Price
Contineum Therapeutics, Analyst Ratings
Contineum Therapeutics,'s analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Contineum Therapeutics, stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Contineum Therapeutics,'s financials, market performance, and future outlook by experienced professionals. Contineum Therapeutics,'s historical ratings below, therefore, can serve as a valuable tool for investors.Contineum Therapeutics,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 188.34 M.Market Cap |
|
Contineum Therapeutics,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.21) | (0.20) |
Determining Contineum Therapeutics,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Contineum Therapeutics, is a good buy. For example, gross profit margin measures Contineum Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Contineum Therapeutics,'s profitability and make more informed investment decisions.
Basic technical analysis of Contineum Stock
As of the 28th of March, Contineum Therapeutics, shows the Risk Adjusted Performance of (0.17), standard deviation of 3.88, and Mean Deviation of 2.84. Contineum Therapeutics, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Contineum Therapeutics, variance and potential upside to decide if Contineum Therapeutics, is priced correctly, providing market reflects its regular price of 7.07 per share. Given that Contineum Therapeutics, has information ratio of (0.20), we suggest you to validate Contineum Therapeutics, Class's prevailing market performance to make sure the company can sustain itself at a future point.Contineum Therapeutics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Contineum Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Contineum Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Contineum Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stengone Carmine N. over a month ago Acquisition by Stengone Carmine N. of 300000 shares of Contineum Therapeutics, at 9.79 subject to Rule 16b-3 | ||
Johnson & Johnson over six months ago Discretionary transaction by Johnson Johnson of tradable shares of Contineum Therapeutics, subject to Rule 16b-3 |
Understand Contineum Therapeutics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Contineum Therapeutics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | 0.7351 | |||
| Mean Deviation | 2.84 | |||
| Coefficient Of Variation | (481.64) | |||
| Standard Deviation | 3.88 | |||
| Variance | 15.05 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.88) | |||
| Total Risk Alpha | (0.57) | |||
| Treynor Ratio | 0.7251 | |||
| Maximum Drawdown | 17.27 | |||
| Value At Risk | (6.58) | |||
| Potential Upside | 6.09 | |||
| Skewness | 0.1543 | |||
| Kurtosis | 0.768 |
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | 0.7351 | |||
| Mean Deviation | 2.84 | |||
| Coefficient Of Variation | (481.64) | |||
| Standard Deviation | 3.88 | |||
| Variance | 15.05 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.88) | |||
| Total Risk Alpha | (0.57) | |||
| Treynor Ratio | 0.7251 | |||
| Maximum Drawdown | 17.27 | |||
| Value At Risk | (6.58) | |||
| Potential Upside | 6.09 | |||
| Skewness | 0.1543 | |||
| Kurtosis | 0.768 |
Consider Contineum Therapeutics,'s intraday indicators
Contineum Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Contineum Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Contineum Therapeutics, Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 31st of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Contineum Stock media impact
Far too much social signal, news, headlines, and media speculation about Contineum Therapeutics, that are available to investors today. That information is available publicly through Contineum media outlets and privately through word of mouth or via Contineum internal channels. However, regardless of the origin, that massive amount of Contineum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Contineum Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Contineum Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Contineum Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Contineum Therapeutics, alpha.
Contineum Therapeutics, Corporate Management
| John Healy | General Secretary | Profile | |
| Steve Kunszabo | Senior Communications | Profile | |
| Austin Chen | Senior Research | Profile | |
| Morgan Paulsen | Senior Accounting | Profile | |
| Julie Iwashita | Senior Operations | Profile | |
| Peter CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Contineum Therapeutics, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Contineum Therapeutics,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.